Compare NICE Ltd (NICE) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Nuwellis Inc — how do they compare? NICE Ltd trades at $117 (market cap $6.81B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: NICE Ltd is far larger — about 3095.5× Nuwellis Inc's market cap, and NICE Ltd is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NICE Ltd for 15 Days and Nuwellis Inc for 26 Days on average.
| NICE | NUWE | |
|---|---|---|
Market Cap | $6.81B | $2.20M |
Volume | 382,395 | 121,544 |
Sector | Technology | Health |
52-Week High | $137.68 | $146.65 |
52-Week Low | $83.15 | $0.68 |
Typical Hold Time | 15 Days | 26 Days |
Enterprise Value | $6.54B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE Ltd. (NICE) trades at $116.42, up 0.95% on the day, with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 17.08 and strong profitability margins, including a 65.12% gross margin. Recent earnings have consistently beaten expectations, and analyst consensus is bullish with a $124.20 price target. Business developments include being named a leader in IDC MarketScape for contact center platforms, highlighting its competitive position in AI-driven customer experience solutions.
The outlook for NICE is positive, supported by AI-driven growth and a reasonable valuation. Investment opportunities include continued cloud and AI revenue expansion, while risks involve margin compression from heavy investment and market volatility. With no sell ratings from analysts and institutional buying activity, the stock presents a favorable risk-reward profile for growth-oriented investors.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
